Jean‐Baptiste Assié

1.5k total citations
38 papers, 551 citations indexed

About

Jean‐Baptiste Assié is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jean‐Baptiste Assié has authored 38 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 28 papers in Oncology and 3 papers in Surgery. Recurrent topics in Jean‐Baptiste Assié's work include Lung Cancer Treatments and Mutations (21 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Lung Cancer Diagnosis and Treatment (11 papers). Jean‐Baptiste Assié is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Lung Cancer Diagnosis and Treatment (11 papers). Jean‐Baptiste Assié collaborates with scholars based in France, United States and Réunion. Jean‐Baptiste Assié's co-authors include C. Chouaïd, Boris Duchemann, Thierry Landré, Olivier Bylicki, Kader Chouahnia, Anne-Françoise Gaudin, François-Emery Cotté, R. Corre, N. Paleiron and Matteo Giaj Levra and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Cancers.

In The Last Decade

Jean‐Baptiste Assié

36 papers receiving 546 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean‐Baptiste Assié France 14 359 322 65 62 43 38 551
Elisa Bordón Spain 15 172 0.5× 100 0.3× 169 2.6× 169 2.7× 48 1.1× 20 450
J. Casal Spain 10 195 0.5× 170 0.5× 40 0.6× 10 0.2× 30 0.7× 29 327
Estelamari Rodríguez United States 10 191 0.5× 160 0.5× 126 1.9× 20 0.3× 35 0.8× 50 376
Sarah Mills United Kingdom 8 313 0.9× 64 0.2× 91 1.4× 19 0.3× 57 1.3× 15 451
Sita Andarini Indonesia 9 213 0.6× 98 0.3× 76 1.2× 44 0.7× 19 0.4× 37 468
Abdallah Flaifel United States 11 175 0.5× 259 0.8× 179 2.8× 13 0.2× 65 1.5× 21 440
Ryan Geschwindt United States 10 80 0.2× 137 0.4× 94 1.4× 13 0.2× 35 0.8× 15 337
Anna Paterson United Kingdom 13 92 0.3× 101 0.3× 92 1.4× 15 0.2× 131 3.0× 40 336
Patricia Lorenzo-Luaces Cuba 10 115 0.3× 73 0.2× 36 0.6× 22 0.4× 34 0.8× 20 290

Countries citing papers authored by Jean‐Baptiste Assié

Since Specialization
Citations

This map shows the geographic impact of Jean‐Baptiste Assié's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Baptiste Assié with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Baptiste Assié more than expected).

Fields of papers citing papers by Jean‐Baptiste Assié

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Baptiste Assié. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Baptiste Assié. The network helps show where Jean‐Baptiste Assié may publish in the future.

Co-authorship network of co-authors of Jean‐Baptiste Assié

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Baptiste Assié. A scholar is included among the top collaborators of Jean‐Baptiste Assié based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Baptiste Assié. Jean‐Baptiste Assié is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chouaïd, C., Jean‐Baptiste Assié, & J.B. Auliac. (2025). Papillon trial, a major advance in the management of patients with metastatic, mutated-EGFR exon 20 insertion non-small-cell lung cancer. Chinese Clinical Oncology. 14(1). 15–15. 1 indexed citations
2.
Landré, Thierry, Abdoulaye Karaboué, Zachary S. Buchwald, et al.. (2024). Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis. ESMO Open. 9(2). 102220–102220. 32 indexed citations
3.
Naulleau, G., Isabelle Monnet, F. Viñas, et al.. (2024). Double immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case report. Translational Lung Cancer Research. 13(9). 2448–2452.
4.
Assié, Jean‐Baptiste, C. Chouaïd, Hilario Nunès, et al.. (2023). Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting. Therapeutic Advances in Medical Oncology. 15. 2597583–2597583. 4 indexed citations
5.
Jamme, Philippe, Jean‐Baptiste Assié, Rémi Veillon, et al.. (2023). Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study. Targeted Oncology. 18(4). 585–591. 3 indexed citations
6.
Seban, Romain‐David, Kader Chouahnia, Jean‐Baptiste Assié, et al.. (2023). Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy. Cancers. 15(8). 2223–2223. 2 indexed citations
7.
Assié, Jean‐Baptiste, Emmanuel Grolleau, Anthony Canellas, et al.. (2022). Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study. Cancers. 14(6). 1498–1498. 11 indexed citations
8.
Chouaïd, C., R. Corre, Matteo Giaj Levra, et al.. (2022). Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab. JCO Clinical Cancer Informatics. 6(6). e2100108–e2100108. 6 indexed citations
9.
Assié, Jean‐Baptiste, et al.. (2021). Factors associated with early lung cancer mortality: a systematic review. Expert Review of Anticancer Therapy. 21(10). 1125–1133. 10 indexed citations
10.
Assié, Jean‐Baptiste, I. Monnet, Marie-Ange Massiani, et al.. (2020). Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14–skipping mutation: A series of 6 cases. Lung Cancer. 150. 21–25. 39 indexed citations
11.
Bylicki, Olivier, F. Rivière, Florence Canouï‐Poitrine, et al.. (2020). Factors Associated With Aggressiveness of End-of-Life Care for Lung Cancer Patients and Associated Costs of Care. Clinical Lung Cancer. 22(3). e320–e328. 10 indexed citations
12.
Landré, Thierry, Gaëtan Des Guetz, Kader Chouahnia, et al.. (2020). First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. Journal of Cancer Research and Clinical Oncology. 146(12). 3333–3339. 17 indexed citations
13.
Levra, Matteo Giaj, François-Emery Cotté, R. Corre, et al.. (2019). MA07.06 Immunotherapy Re-Challenge After Nivolumab Treatment in Advanced Non-Small Cell Lung Cancer in French Real-World Setting. Journal of Thoracic Oncology. 14(10). S274–S275. 2 indexed citations
14.
Monnet, I., Marie-Ange Massiani, Jean‐Baptiste Assié, et al.. (2019). MA03.09 Dramatic Responses to Immune Checkpoint Inhibitors in MET Exon 14 Skipping Mutation (METex14mut) Non Small Cell Lung Cancers. Journal of Thoracic Oncology. 14(10). S259–S259. 2 indexed citations
15.
Assan, Florence, F. Schlemmer, Jean‐Baptiste Assié, et al.. (2019). Atypical systemic sarcoid-like granulomatosis in two patients treated with BRAF and MEK inhibitors. European Journal of Dermatology. 29(5). 556–557. 6 indexed citations
16.
Levra, Matteo Giaj, François-Emery Cotté, R. Corre, et al.. (2019). Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Lung Cancer. 140. 99–106. 88 indexed citations
17.
Assié, Jean‐Baptiste, François-Emery Cotté, Matteo Giaj Levra, et al.. (2019). P2.04-03 Nivolumab Outcomes in Octogenarian Patients with Advanced Non-Small Cell Lung Cancer in French Real-World Setting. Journal of Thoracic Oncology. 14(10). S708–S708. 1 indexed citations
18.
Bylicki, Olivier, et al.. (2019). First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. BioDrugs. 33(2). 159–171. 45 indexed citations
19.
Guisier, Florian, R. Gervais, Jean‐Baptiste Assié, et al.. (2019). Local ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumour response to anti-PD1 treatment. Annals of Oncology. 30. v620–v621. 4 indexed citations
20.
Rodier, Anne, et al.. (1995). Breeding maize lines for complete and partial resistance to maize streak virus (MSV). Euphytica. 81(1). 57–70. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisa Bordón Breakdown of academic impact, for papers by J. Casal Breakdown of academic impact, for papers by Estelamari Rodríguez Breakdown of academic impact, for papers by Sarah Mills Breakdown of academic impact, for papers by Sita Andarini Breakdown of academic impact, for papers by Abdallah Flaifel Breakdown of academic impact, for papers by Ryan Geschwindt Breakdown of academic impact, for papers by Anna Paterson Breakdown of academic impact, for papers by Patricia Lorenzo-Luaces
Rankless by CCL
2026